Proposed pharmacovigilance fees unjustifiably high, says EU generics industry
This article was originally published in SRA
Executive Summary
The fees rates proposed by the European Commission for implementing the new pharmacovigilance law are "unjustifiably high" and could result in an average-sized generic medicines company paying €20 million ($26 million) – the highest possible amount – in annual pharmacovigilance fees alone, the European generic medicines industry association, the EGA, has warned1.